Literature DB >> 15039326

Flea-borne transmission model to evaluate vaccine efficacy against naturally acquired bubonic plague.

Clayton O Jarrett1, Florent Sebbane, Jeffrey J Adamovicz, Gerard P Andrews, B Joseph Hinnebusch.   

Abstract

A flea-to-mouse transmission model was developed for use in testing new candidate vaccines for the ability to protect against flea-borne plague. The model was used to evaluate a recombinant fusion protein vaccine consisting of the Yersinia pestis F1 and V antigens. After one to three challenges with Y. pestis-infected fleas, 14 of 15 unvaccinated control mice developed plague, with an average septicemia level of 9.2 x 10(8) Y. pestis CFU/ml. None of 15 vaccinated mice developed the disease after similar challenges, and serological testing indicated that transmitted bacteria were eliminated by the immune system before extensive replication and systemic infection could occur. The transmission and development of disease in control mice correlated with the number of bites by blocked fleas but not with the total number of fleabites. The model provides a means to directly assess the efficacy of new vaccines to prevent naturally acquired bubonic plague and to study events at the vector-host interface that lead to dissemination and disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15039326      PMCID: PMC375218          DOI: 10.1128/IAI.72.4.2052-2056.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Infectivity of Plasmodium berghei sporozoites delivered by intravenous inoculation versus mosquito bite: implications for sporozoite vaccine trials.

Authors:  J A Vaughan; L F Scheller; R A Wirtz; A F Azad
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

Review 2.  Modulation of host immunity by haematophagous arthropods.

Authors:  G B Schoeler; S K Wikel
Journal:  Ann Trop Med Parasitol       Date:  2001-12

3.  Transmission factors: Yersinia pestis genes required to infect the flea vector of plague.

Authors:  B Joseph Hinnebusch
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

4.  LXXXI. Further notes on the mechanism of the transmission of plague by fleas.

Authors:  A W Bacot
Journal:  J Hyg (Lond)       Date:  1915-01

5.  LXVII. Observations on the mechanism of the transmission of plague by fleas.

Authors:  A W Bacot; C J Martin
Journal:  J Hyg (Lond)       Date:  1914-01

6.  Multidrug resistance in Yersinia pestis mediated by a transferable plasmid.

Authors:  M Galimand; A Guiyoule; G Gerbaud; B Rasoamanana; S Chanteau; E Carniel; P Courvalin
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

7.  Survival and reproduction of artificially fed cat fleas, Ctenocephalides felis Bouché (Siphonaptera: Pulicidae).

Authors:  S E Wade; J R Georgi
Journal:  J Med Entomol       Date:  1988-05       Impact factor: 2.278

8.  Characterization of the salivary apyrase activity of three rodent flea species.

Authors:  J M Ribeiro; J A Vaughan; A F Azad
Journal:  Comp Biochem Physiol B       Date:  1990

9.  Role of the Yersinia pestis hemin storage (hms) locus in the transmission of plague by fleas.

Authors:  B J Hinnebusch; R D Perry; T G Schwan
Journal:  Science       Date:  1996-07-19       Impact factor: 47.728

10.  Evaluation of the role of the Yersinia pestis plasminogen activator and other plasmid-encoded factors in temperature-dependent blockage of the flea.

Authors:  B J Hinnebusch; E R Fischer; T G Schwan
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

View more
  11 in total

1.  Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis.

Authors:  Debaditya Bhattacharya; Joan Mecsas; Linden T Hu
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

2.  Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens.

Authors:  Sabena Uddowla; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-10-02       Impact factor: 3.641

3.  Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.

Authors:  Audrey Glynn; Chad J Roy; Bradford S Powell; Jeffrey J Adamovicz; Lucy C Freytag; John D Clements
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice.

Authors:  Sarah S Bubeck; Angelene M Cantwell; Peter H Dube
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

5.  Delineation and analysis of chromosomal regions specifying Yersinia pestis.

Authors:  Anne Derbise; Viviane Chenal-Francisque; Christèle Huon; Corinne Fayolle; Christian E Demeure; Béatrice Chane-Woon-Ming; Claudine Médigue; B Joseph Hinnebusch; Elisabeth Carniel
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

6.  Yersinia pestis IS1541 transposition provides for escape from plague immunity.

Authors:  Claire A Cornelius; Lauriane E Quenee; Derek Elli; Nancy A Ciletti; Olaf Schneewind
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

7.  The Yersinia pestis caf1M1A1 fimbrial capsule operon promotes transmission by flea bite in a mouse model of bubonic plague.

Authors:  Florent Sebbane; Clayton Jarrett; Donald Gardner; Daniel Long; B Joseph Hinnebusch
Journal:  Infect Immun       Date:  2008-12-22       Impact factor: 3.441

8.  The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague.

Authors:  E D Williamson
Journal:  Adv Prev Med       Date:  2011-09-29

9.  Model systems to study plague pathogenesis and develop new therapeutics.

Authors:  Matthew B Lawrenz
Journal:  Front Microbiol       Date:  2010-11-04       Impact factor: 5.640

Review 10.  Plague: Infections of Companion Animals and Opportunities for Intervention.

Authors:  Petra C F Oyston; Diane Williamson
Journal:  Animals (Basel)       Date:  2011-06-21       Impact factor: 2.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.